kp104
mAbexperimentalBi-specific
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 30, 2020 (NCT05490017)
Timeline
Indications
Mechanism of action
- Complement factor HINHIBITOR
CFH inhibitor
C5AR1 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05476887 | Phase 2 | Feb 28, 2023 | Kira Pharmacenticals (US), LLC. |
| NCT05517980 | Phase 2 | Dec 31, 2022 | Kira Pharmacenticals (US), LLC. |
| NCT05504187 | Phase 2 | Nov 30, 2022 | Kira Pharmacenticals (US), LLC. |
| NCT05490017 | Phase 1 | Dec 30, 2020 | Kira Pharmacenticals (US), LLC. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kira Pharmacenticals (US), LLC. | For profit | 4 | 4 | 2 | 2020 |
1 organizations
Page 1 / 1